• 四川大學(xué)華西醫(yī)院,心內(nèi)科,成都,610041;

目的 　了解葛根素治療冠心病心絞痛的臨床研究現(xiàn)狀,并評(píng)價(jià)其能否為臨床應(yīng)用提供高質(zhì)量的依據(jù).
方法 　按文內(nèi)所述檢索策略,計(jì)算機(jī)檢索1966年至2003年10月在國(guó)內(nèi)外公開(kāi)發(fā)表的有關(guān)葛根素治療冠心病心絞痛的所有文獻(xiàn),并對(duì)所納入的文獻(xiàn)按國(guó)際臨床流行病學(xué)標(biāo)準(zhǔn)進(jìn)行分析.
結(jié)果 　共檢索到文獻(xiàn)202篇,納入138篇,其中隨機(jī)對(duì)照研究106篇,但僅有1篇屬高質(zhì)量研究;有對(duì)照未隨機(jī)分組的研究8篇;無(wú)對(duì)照的系列病例觀察研究24篇.126篇有診斷標(biāo)準(zhǔn),10篇有納入標(biāo)準(zhǔn),3篇為半隨機(jī)分配,1篇為雙盲,4篇為單盲,無(wú)隨訪研究,117篇報(bào)告了不良反應(yīng).
結(jié)論 　目前葛根素治療冠心病心絞痛臨床研究的方法學(xué)質(zhì)量尚低,還不能為臨床應(yīng)用提供可靠的依據(jù).

引用本文： 龍波,陳玉成,陳懷生,曾智. 葛根素治療冠心病心絞痛的臨床研究文獻(xiàn)評(píng)價(jià). 中國(guó)循證醫(yī)學(xué)雜志, 2004, 04(5): 333-336. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)循證醫(yī)學(xué)雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. ［1］Beller. George A. Coronary Heart Disease in the First 30 Years of the 21st Century: Challenges and Opportunities: The 33rd Annual James B. Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association[J]. Circulation,2001 ;103(20) :2 428-2 435.
2. ［2］Wang L, Zhai AP, Chai XS. The Vitro Action of Purarin On Cats Vascular Smooth Muscle[J]. Acta Pharmacologica Sinica,1994;15(2) :180 -182.
3. ［3］Zhou JH, Zhou H, Liu XR. Effet of Purarin Injection on Blood Fat and Hemotheology[J]. J Med Thero ＆ Prac, 2000;13(1) :40.
4. ［4］Clarke M, Oxman AD, editors. Cochrane Reviever’ s handbook 4.1 [ M/CD ] [ Update 2000 ]. In Review Manager (RevMan) [ Computer program], Version4.1. Oxford, England: The Cochrane Collaboration, 2000.
5. ［5］Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,Gavaghan DJ, McQuary HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary [ J ] ? Controlled Clin Trials, 1996 ; 17(1): 1-12.
6. ［6］Liu M, Zhang SH. New Knowledge: Intention-to-Treat Analysis in Clinical Trail[J]. BMJ Chinese Edition, 2001;4(4) :223 -224.
7. 劉鳴,張世洪.新知識(shí):臨床試驗(yàn)中的意向處理分析[J].英國(guó)醫(yī)學(xué)雜志中文版,2001;4(4):223～224.
  1. 1. ［1］Beller. George A. Coronary Heart Disease in the First 30 Years of the 21st Century: Challenges and Opportunities: The 33rd Annual James B. Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association[J]. Circulation,2001 ;103(20) :2 428-2 435.
  2. 2. ［2］Wang L, Zhai AP, Chai XS. The Vitro Action of Purarin On Cats Vascular Smooth Muscle[J]. Acta Pharmacologica Sinica,1994;15(2) :180 -182.
  3. 3. ［3］Zhou JH, Zhou H, Liu XR. Effet of Purarin Injection on Blood Fat and Hemotheology[J]. J Med Thero ＆ Prac, 2000;13(1) :40.
  4. 4. ［4］Clarke M, Oxman AD, editors. Cochrane Reviever’ s handbook 4.1 [ M/CD ] [ Update 2000 ]. In Review Manager (RevMan) [ Computer program], Version4.1. Oxford, England: The Cochrane Collaboration, 2000.
  5. 5. ［5］Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,Gavaghan DJ, McQuary HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary [ J ] ? Controlled Clin Trials, 1996 ; 17(1): 1-12.
  6. 6. ［6］Liu M, Zhang SH. New Knowledge: Intention-to-Treat Analysis in Clinical Trail[J]. BMJ Chinese Edition, 2001;4(4) :223 -224.
  7. 7. 劉鳴,張世洪.新知識(shí):臨床試驗(yàn)中的意向處理分析[J].英國(guó)醫(yī)學(xué)雜志中文版,2001;4(4):223～224.